Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study

BACKGROUND: Fimasartan is a novel angiotensin II receptor blocker. Fimasartan is mainly eliminated via biliary excretion, and its urinary elimination is less than 3%. OBJECTIVE: Based on guidance from the United States Food and Drug Administration, a reduced pharmacokinetic (PK) study was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seokuee, Lee, Jongtae, Shin, Donghoon, Lim, Kyoung Soo, Kim, Yon Su, Jang, In-Jin, Yu, Kyung-Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199969/
https://www.ncbi.nlm.nih.gov/pubmed/25336916
http://dx.doi.org/10.2147/DDDT.S68784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199969/
https://www.ncbi.nlm.nih.gov/pubmed/25336916
http://dx.doi.org/10.2147/DDDT.S68784

Ejemplares similares